This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Asthma Drugs Educe FDA Worry

The Food and Drug Administration on Friday issued a public health advisory about potentially fatal side effects from two GlaxoSmithKline (GSK - Get Report) asthma drugs. The company vigorously disputed the FDA's analysis.

The agency is asking the maker of the drugs, Advair Diskus and Serevent Diskus, to add warnings to their labels that these medications "may increase the chance of severe asthma episodes, and death when those episodes occur."

Advair is GlaxoSmithKline's biggest product, with $4 billion in sales during the first nine months of 2005. Serevent's sales were $450 million. By late afternoon, the company's stock was down $2.20, or 4.2%, to $49.85 on trading that was more than triple the average daily trade for the past three months.

The FDA made the same request of Schering-Plough (SGP) and Novartis (NVS - Get Report), which make and sell a similar asthma product called Foradil Aerolizer. They had no immediate comment.

Schering-Plough's stock was up 23 cents, or 1.2%, to $19.73, and Novartis was adding 29 cents to $54.15.

Each of the drugs cited by the FDA is a long-acting beta 2-adrenergic agonist, or LABA, which provides asthma relief by relaxing muscles around the airways to the lungs. Although they can reduce the number of asthma episodes, the FDA says they "may increase the chances of a severe asthma episode when they do occur."

In one study, the agency says, "an increased number of people taking a LABA in addition to their usual asthma care died from their asthma compared to people taking a placebo in addition to their usual asthma care, although the number of asthma deaths in the study was small."

The FDA proposal is "inconsistent" with treatment guidelines established by the National Institutes of Health, as well as "the standard of care for asthma treatment, which could put many patients at risk of uncontrolled asthma," GlaxoSmithKline said.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GSK $40.72 -0.59%
NVS $85.58 -0.30%
AAPL $119.03 1.00%
FB $105.10 -0.33%
GOOG $750.00 -0.04%


Chart of I:DJI
DOW 17,781.26 -17.23 -0.10%
S&P 500 2,085.59 -4.52 -0.22%
NASDAQ 5,122.7910 -4.7340 -0.09%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs